米氮平和阿米替林治疗躯体化障碍的对照研究

目的:比较米氮平和阿米替林治疗强迫症的疗效和不良反应。方法:以CCMD-2作为诊断标准,用SCL-90,TESS量表评定临床疗效和不良反应,对60例患者进行8周治疗。结果:米氮平与阿米替林疗效相近,两者无显著差异(P>0·05),米氮平不良反应明显少于阿米替林(P<0·01),而且耐受性好。结论:米氮平治疗躯体化障碍与阿米替林相当,但米氮平具有口服剂量小,给药方法简便,不良反应等优点。

A Controlled Study of Mirtazapine and Amitrptyline in Somatization

OBJECTIVE:To compare curative effects, adverse reactions and the safety of mirtazapine and amitriptyline in the treatment of obsession . METHODS:60 patients with somatization disorder were randomly divided into study group (n=30, took mirtazapine) and control group (n=30, took amitriptyline).Curative effects were evaluated with SCL-90 before and at the end of treatment ,at the 2nd, fourth and eighth week of treatment,respectively. Adverse reactions were evaluated with TESS. RESULTS: Curative effects of mirtazapine and amitriptyline were 93.3% and 90% respectively, there was no significant difference(P>0.05). Adverse reactions of the former were significantly fewer than that of the latter (P<0.01), and it also had good tolerance. CONCLUSION: Curative effect of mirtazapine is correspond to that of amitriptyline, but adverse reactions are fewer. Mirtazapine is a safe and effective new antidepressant.